What should I do if I become resistant to Dasatinib?

Dasatinib (Dasatinib) is a drug used to treat chronic myeloid leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL). Although dasatinib is effective in many patients, sometimes patients may develop resistance to the drug.

If a patient develops resistance to dasatinib, first, consult your doctor. They can assess the patient's situation and provide the most appropriate advice, possibly conducting further tests to confirm whether resistance has indeed developed. In some cases, increasing the dose or frequency of dasatinib may help overcome resistance. However, this should be done under the guidance of a medical professional and the risks and benefits need to be weighed.

If a patient develops resistance to dasatinib, doctors may consider other treatment options. For example, they may consider switching to other targeted drugs or stem cell transplantation. Another option is to participate in a relevant clinical trial. Clinical trials may test new treatments or drugs that may help a patient's condition, but patients should also ask their doctor if there are appropriate clinical trials to participate in.

The original drug of dasatinib has been launched in China and is included in the medical insurance. Currently, reimbursement is only available to eligible patients. Common specifications The price of each box of 50mg*60 tablets may be around RMB 10,000. The original drug overseas is even more expensive. Dasatinib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 50mg*60 tablets produced by an Indian pharmaceutical factory may be several hundred yuan (the price may fluctuate due to exchange rates).